TriangleFOR PATIENTS · SOURCE READING
Treatment of Recurrent or Refractory Chronic Lymphocytic Leukemia
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 15, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
The treatment of recurrent or refractory chronic lymphocytic leukemia (CLL) may include therapies and clinical trials.
Source links and citations
Targeted therapy with any of the following drugs:
Source links and citations
Targeted therapy with any of the following drugs:
A tyrosine kinase inhibitor (acalabrutinib, zanubrutinib, or ibrutinib).
Source links and citations
Targeted therapy with any of the following drugs:
Venetoclax with or without obinutuzumab or rituximab.
Source links and citations
Targeted therapy with any of the following drugs:
Ofatumumab with or without chemotherapy.
Source links and citations
Chemotherapy with or without rituximab.
Source links and citations
Immunotherapy (lenalidomide) with or without rituximab.
Source links and citations
Bone marrow or peripheral blood stem cell transplantation.
Source links and citations
Radiation therapy as palliative treatment to relieve symptoms and improve quality of life.
Source links and citations
A clinical trial of CAR T-cell therapy.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice